Fatty liver cirrhosis before 50 is distinct—and often missed

Clinical takeaway: In younger adults with MASLD, type 2 diabetes or obesity should prompt a closer look at fibrosis than an age-weighted score alone provides. 

Metabolic dysfunction-associated steatotic liver disease (MASLD) moves slowly as a rule. Advanced scarring typically concentrates in patients in their late 50s and beyond. The fibrosis scores that decide who gets worked up also bake that age curve in. Younger patients with fatty liver, even with type 2 diabetes and severe obesity, tend to leave the visit without evaluation for cirrhosis. 

Some of those patients are already cirrhotic, and clinicians have had little to identify them by. Whether they differ from patients who progress on the usual timetable, or are simply on the same road sooner, has not been settled. A new analysis from a national biopsy-confirmed MASLD cohort characterizes these patients directly: younger-onset cirrhosis is a distinct phenotype with identifiable risk factors, in a disease found in roughly one in four US adults aged 18 to 24 by the most recent national surveillance. 

One-quarter of participants with MASLD cirrhosis presented before age 50, and their risk profile set them apart. In MASLD patients under 50, type 2 diabetes carried nearly fourfold odds of cirrhosis, and a high genetic risk score more than doubled the odds. Both associations held after adjustment for demographic and metabolic factors. The risks also compounded: cirrhosis prevalence in patients under 50 ran from 2% with neither diabetes nor high genetic risk to nearly 11% with both, a fivefold spread. 

The genetics tilted toward susceptibility in a second way. The protective HSD17B13 variant appeared in 24% of younger-onset cirrhosis cases against 34% of those presenting later, so the younger group more often lacked the allele that ordinarily buffers against progression. 

The screening gap ran alongside the risk profile. Thirty percent of younger-onset cases scored below the Fibrosis-4 (FIB-4) threshold of 1.3 that would prompt further evaluation, and the AST-to-platelet ratio index (APRI) discriminated worse than FIB-4 in this group. Their biopsies also showed more fat at the same stage of scarring, and compared with their non-cirrhotic peers, these patients more often had a BMI of 35 or higher, higher alkaline phosphatase, and lower ALT. That last value can read as reassuring on a routine panel. 

The analysis drew on 2,395 adults with biopsy-proven MASLD enrolled in the NASH Clinical Research Network across nine US centers, 234 of whom had cirrhosis. Younger-onset cirrhosis was defined as the lowest age quartile among cirrhosis cases, which fell below age 50 and comprised 53 patients. The genetic risk score summed risk alleles in PNPLA3 and TM6SF2 plus the wild-type HSD17B13 allele, dichotomized at the median, and multivariable models compared these patients with 999 non-cirrhotic MASLD participants under 50. 

The findings hand clinicians a risk profile before they have a tool built for it. The concrete work going forward is twofold: validating fibrosis assessment that performs in younger patients, and defining a clinical role for the genetic score. The American Association for the Study of Liver Diseases (AASLD) currently does not recommend genetic testing in MASLD. Cirrhosis is also the entry criterion for hepatocellular carcinoma surveillance, so earlier identification would pull cancer screening forward with it. 

"Our findings show that younger adults who develop cirrhosis from MASLD are not simply experiencing the same disease earlier," said Rohit Loomba, MD, senior author of the study, gastroenterologist and hepatologist at UC San Diego Health and chief of the Division of Gastroenterology and Hepatology at UC San Diego School of Medicine. "They appear to have a unique combination of genetic susceptibility and metabolic risk factors that accelerate progression to advanced liver disease." 

Source: Ajmera V, et al. (2026 Sep 16) Clin Gastroenterol Hepatol. Risk Factors and Definition of Younger-Onset Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Cirrhosis